![Marc Voigt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marc Voigt
Directeur Général chez
IMMUTEP LIMITED
Fortune : 567 275 $ au 31/05/2026
Profil
Marc Voigt currently works at Immutep Ltd., as Chief Executive Officer & Executive Director, Immutep SAS, as Chairman-Supervisory Board & President from 2015, Immutep GmbH, as Co-Managing Director, and Pharma-Lizenz-Club Deutschland, as Member.
Mr. Voigt also formerly worked at Elanix Biotechnologies AG, as Vice Chairman-Supervisory Board, Medical Enzymes AG, as Director-Finance, Legal & Business Development from 2001 to 2006, Allianz SE, as Principal from 2001 to 2009, Revotar Biopharmaceuticals AG, as Chief Financial Officer from 2003 to 2006, Allianz Versicherungs AG, as Principal, caprotec bioanalytics GmbH, as MD, Chief Operating & Financial Officer, and Immutep GmbH, as General Manager-European Operations.
Mr. Voigt received his Masters Business Admin degree from Freie Universität Berlin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUTEP LTD 1,01 % | 18/03/2026 | 14 877 395 ( 1,01 % ) | 567 275 $ | 31/05/2026 |
Postes actifs de Marc Voigt
| Sociétés | Poste | Début |
|---|---|---|
| IMMUTEP LIMITED | Directeur Général | 09/07/2014 |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Immutep SAS
 Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Président | 18/11/2015 |
Immutep GmbH
 Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Directeur Général | - |
Anciens postes connus de Marc Voigt
| Sociétés | Poste | Fin |
|---|---|---|
Medical Enzymes AG
 Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Directeur Financier/CFO | 02/01/2006 |
Revotar Biopharmaceuticals AG
 Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Directeur Financier/CFO | 02/01/2006 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Corporate Officer/Principal | - |
| ELANIX BIOTECHNOLOGIES AG | Directeur/Membre du Conseil | - |
caprotec bioanalytics GmbH
 caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Directeur Financier/CFO | - |
Formation de Marc Voigt
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
27
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Allianz SE
 Allianz SE Multi-Line InsuranceFinance Provides property, casualty, life and health insurance and asset management services | Finance |
Immutep Ltd.
 Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Elanix Biotechnologies AG
 Elanix Biotechnologies AG BiotechnologyHealth Technology Develops and commercializes products for acute wound care, dermatological, and gynecological applications | Health Technology |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Health Technology |
Allianz Versicherungs AG
 Allianz Versicherungs AG Multi-Line InsuranceFinance Provides motor, property, liability and accident insurance services | Finance |
Freie Universität Berlin
 Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Health Technology |
Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Health Technology |
Choisissez Zonebourse 
